Item 1(a). | Name of Issuer: |
Zymeworks Inc. (the “Issuer”)
Item 1(b). | Address of Issuer’s Principal Executive Offices: |
Suite 540, 1385 West 8th Avenue, Vancouver, British Columbia, Canada
Item 2(a). | Names of Persons Filing: |
The names of the persons filing this report (collectively, the “Reporting Persons”) are:
Perceptive Advisors LLC (“Perceptive Advisors”)
Joseph Edelman (“Mr. Edelman”)
Perceptive Life Sciences Master Fund, Ltd. (the “Master Fund”)
Item 2(b). | Address of Principal Business Office or, if None, Residence: |
The address of the principal business office of each of the Reporting Persons is:
51 Astor Place, 10th Floor
New York, NY 10003
Perceptive Advisors is a Delaware limited liability company
Mr. Edelman is a United States citizen
The Master Fund is a Cayman Islands corporation
Item 2(d). | Title of Class of Securities: |
Common Shares, no par value (“Common Shares”)
98985W 902
Item 3. | If this statement is filed pursuant to§§240.13d-1(b) or240.13d-2(b) or (c), checkwhether the person filing is a: |
Not applicable.
The information required by this item with respect to each Reporting Person is set forth in Rows 5 through 9 and 11 of the cover page to this Schedule 13G. The ownership percentages reported are based on 39,137,074 outstanding Common Shares as reported in the Issuer’s prospectus supplement filed on June 20, 2019 and giving effect to the additional shares issued and sold pursuant to the underwriters’ option.